Cellular Plasticity and Disease news

<p>Manuel Serrano, group leader of the Cellular Plasticity and Disease laboratory</p>
4 Apr 2018

La Opinión A Coruña, La Nueva España, Faro de Vigo, among other media, have published an interview with Manuel Serrano, head of the Cellular Plasticity and Disease Lab at IRB Barcelona, about his career and the work being done at the centre.

Link to La Opinión A Coruña

Link to Faro de vigo

 

<p>Manuel Serrano, group leader of the Cellular Plasticity and Disease laboratory</p>
5 Feb 2018

The newspaper ABC has published an article about the group of scientists and medicsl doctors that is facing cancer. In the article, they mention Manuel Serrano, group leader of the Cellular Plasticity and Disease laboratory at IRB Barcelona, who affirms that the great challenge of regenerative medicine is to know how tissues react to damage and how they self-repair.

Link to: ABC.es

<p>Manuel Serrano Lab</p>
19 Jan 2018

It is a factor that has been conserved through evolution, from plants to mammals

RPAP1 regulates the activity of RNA polymerase II by means of its interaction with gene transactivators

<p>Manuel Serrano, group leader of the Cellular Plasticity and Disease laboratory at IRB Barcelona.</p>
22 Dec 2017

La Vanguardia, La Razón, Diario Médico, among other media, have highlighted the recognition given to Manuel Serrano, ICREA Research professor and group leader of the Cellular Plasticity and Disease Lab at IRB Barcelona, for his work "Tissue damage and senescence provide critical signals for reprogramming cellular in vivo". He has been distinguished with the Severo Ochoa Prize for Biomedial Research. It is a project financed by CaixaImpulse, a program of "la Caixa" Bank Foundation and Caixa Capital Risc.

Selected media:

Link to...

<p>Manuel Serrano, group leader of the Cellular Plasticity and Disease laboratory at IRB Barcelona.</p>
20 Dec 2017

The Ferrer Research Foundation acknowledges the various perspectives of his research into cancer and aging.

<p>Elena Meléndez Esteban, recipient of the first "IRB Barcelona Futur” PhD fellowship.</p>
31 Oct 2017

The academic year began with the arrival of 11 new students to IRB Barcelona’s International PhD Programme—among them Elena Meléndez Esteban (b. Barcelona, 1993), the recipient of the first "IRB Barcelona Futur” PhD fellowship. This fellowship has come about from the campaign with the same name launched by the institute in December 2016 to increase public awareness of the importance of biomedical research and PhD training. “So many people have shown such generosity in supporting the PhD training of a young researcher whom they have never met,” says Elena. 

30 Oct 2017

Diario Médico explains, through IRB Barcelona researcher Cristina Pantoja, the research conducted in regenerative medicine in the Cellular Plasticity and Disease laboratory. The specialized newspaper goes on to describe how the incorporation of Manuel Serrano’s lab to IRB Barcelona in May was made possible thanks to the joint effort of ICREA of the Generalitat de Catalunya and the Obra Social "la Caixa".

<p>Elena Meléndez is the first student to be awarded the "IRB Barcelona Futur" fellowship, which has come about through social altruism (Photo: IRB Barcelona)</p>
26 Oct 2017

The “IRB Barcelona Futur” fellowship is funded by donations given to the permanent fundraising campaign “Futur”, which supports the training of young scientists.

The first awardee is a 24-year-old student who graduated in Biomedicine and holds a Master’s from the University of Utrecht and the Gurdon Institute in Cambridge Cambridge.

<p>Manuel Serrano, group leader of the Cellular Plasticity and Disease laboratory at IRB Barcelona.</p>
25 Oct 2017

Scientific American responds to an article originally published in Nature on senescent cells (which have lost the ability to divide) and their impact on premature aging. The author cites ICREA researcher Manuel Serrano, at IRB Barcelona, who has studied the phenomenon of senescence for more than 25 years.

Link to Scientific American

24 Oct 2017

In an extensive article, the channel of science and technology news Néxt/VózPopuli relates how tycoons in Silicon valley are attempting to buy eternal youth.

Manuel Serrano, researcher at IRB Barcelona, and other experts on ageing consulted, consider that there is an investment “bubble” in the anti-aging research field. “It’s great that wealthy people believe that ageing is a condition that can be treated,” he says. “We are starting to get spectacular results in mice and I think there is a sufficient scientific basis for optimism. If I were rich I would also be investing in this,” he concludes.

Read the article here:...